Prostate Cancer

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.

The 1.5T Elekta Unity MR-Linac demonstrated lower rates of erectile dysfunction with neurovascular sparing vs without in patients with intermediate-risk prostate cancer.

A recommendation from an independent data monitoring committee prompted the discontinuation of the phase 3 CAPItello-280 trial.

Data show that patients who undergo grade group 1 prostatectomies may experience an increased likelihood of higher risk features.

BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.